GlassScriptPhysician profile
Laura J Wu
NPI 1649416199
$6,295.21
in general payments reported to CMS, 2019-2025
27 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $267 · 2021: $243 · 2022: $845 · 2023: $807 · 2024: $965 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292 · Travel and Lodging: $1,868 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.03 |
| Travel and Lodging | $1,868.29 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,912.85 | 2022-2025 | Infinity, Proclaim |
| Boston Scientific Corporation | $1,408.19 | 2019-2025 | Vercise, Bodyguardian |
| Abbvie INC. | $1,068.51 | 2022-2025 | Botox, Duopa, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $284.38 | 2020-2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $267.20 | 2019-2024 | Ingrezza, Ongentys |
| Medtronic, INC. | $234.58 | 2022 | |
| Medtronic USA, INC. | $224.01 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $143.16 | 2019-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $130.66 | 2019 | |
| Kyowa Kirin, INC. | $124.24 | 2022 | |
| Allergan, INC. | $63.54 | 2019-2022 | |
| Argenx US, INC. | $63.48 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Adamas Pharmaceuticals, INC. | $48.68 | 2019 | |
| Eisai INC. | $47.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $42.17 | 2022-2024 | Xarelto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32.71 | 2025 | Wainua |
| Merz North America, INC. | $26.74 | 2019 | |
| Lilly USA, LLC | $23.40 | 2019 | |
| Amgen INC. | $22.28 | 2019 | |
| Ge Healthcare | $21.64 | 2024 | |
| Acorda Therapeutics, INC | $18.34 | 2019 | |
| Novo Nordisk INC | $17.42 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.82 | 2021 | |
| Medtronic Minimed, INC. | $15.37 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.55 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.38 | 2019 | |
| Pfizer INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.